Fecal Transplantation to Eradicate Colonizing Emergent Superbugs

Inclusion Criteria: Inclusion Criteria for patients: * ≥ 18 years and \< 105 years * Patient with at least one positive rectal swab for enterobacteria: extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenem-resistant Enterobacteriaceae (CRE), or who have had an ESBL-E or CRE infection within the year For ESBL-E carriers: an ESBL-E infection within the year is mandatory \- Patient able to take 50 capsules orally in a day and without swallowing disorders Inclusion Criteria for healthy volunteers donors: * Healthy subjects ≥ 18 years and \< 50 years * Body mass index \< 30 kg/m\^2 * Regular bowel movement defined as at least 1 stool every 2 daysand maximum than 3 stools per day Exclusion Criteria: Exclusion Criteria for patients: * Current antibiotic treatment with te exception of long term antibiotic prophylaxis (duration of at least 3 months/year) * Patients hospitalized in the intensive care unit * Pregnancy or breastfeeding during the study * Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control \[such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (condoms)\] to avoid pregnancy for the entire study * Patient under legal protection * Participation in another interventional study * Non-affiliation to a social security scheme * Patient under AME * Refusal to participate to the study Exclusion Criteria for healthy volunteers donors: * Any history of or current proctologic disease or any acute condition, which in the investigator's judgment could harm the volunteer and/or compromise or limit the evaluation of the protocol or data analysis (for details, please see protocol) * Subject under legal protection * Participation in any other interventional study * No-affiliation to a social security scheme * Subject under AME * Refusal to participate to the study Randomization criteria: * Patient colonized with a carbapenem-resistant Enterobacteriaceae (CRE) and/or colonized with an extended spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) at inclusion on stool culture * Patient with an ESBL-E infection in the previous 12 months (only for participants no colonized with CRE). * Compatible transplant (FMT) based on patient's serological profile (CMV/EBV) available